Pharma and Life Sciences

Welcome to Europe's hottest event for Pharma and Life Sciences

Why attend HLTH Europe?

Between now and 2033, the expiration of patents on dozens of brand-name medications is expected to create a revenue gap exceeding $200 billion. To bridge this loss, the pharmaceutical industry will increasingly rely on M&A activity, joint ventures, strategic alliances, R&D investment, and diversification. HLTH Europe will help you stay ahead of the curve.


HLTH Europe offers an unparalleled platform to meet and collaborate with leading: 

  • Biotechs

  • Digital health, diagnostics and genomics innovators

  • Contract Research Organisations (CROs)

  • Investors 

  • Senior policy-makers and regulators

  • Health systems 

  • Government ministers


Seize the opportunity to unlock fresh partnerships, fuel your pipeline with transformative solutions, and adapt to evolving market demands. HLTH Europe is your gateway to strategic growth and innovation.

We solve your (business) problems:

Pressure on R&D for cost-effective innovation

Pain point: You need to develop successful new drugs faster and at lower costs due to heightened competition and tighter budgets.

Solution from HLTH Europe: Hosting the Life Science Summit, featuring startup pitch sessions, access to our Health Transformation Summit (which serves as a nexus for those at the forefront of creating and influencing healthcare policy globally), and 1-1 curated networking opportunities through our Market Connect programme bringing you face-to-face with leading innovators, enabling you to discover cutting-edge R&D technologies and partnerships.

Difficulty in identifying the right deals and partnerships

Pain point: We know companies like yours struggle with evaluating opportunities leading them to either committing to ineffective partnerships or missing high-value ones. 

Solution from HLTH Europe: Discover innovative startups through our Market Connect Programme, designed to provide tailored 1:1 introductions and expert advisory services. We help pharma leaders identify and secure strategic partnerships with top-tier companies in the industry. By handpicking the most relevant opportunities, we make it effortless for you to connect with the right partners. You stay in control - choose who you want to meet, ensuring that every interaction is mutually beneficial and impactful.

Patent expiry

Pain point: The expiration of patents on dozens of brand-name medications is leaving a revenue gap you need to find a solution to. 

Solution from HLTH Europe: To bridge this loss, the pharmaceutical industry will increasingly rely on M&A activity, joint ventures, strategic alliances, R&D investment, and diversification. At HLTH Europe you will be able to do all of this, and meet qualified, and vetted partners. 

Uncertainty around digital health investments

Pain Point: Many pharma companies view digital health as a "luxury" rather than a necessity, with budgets fluctuating depending on management priorities. Some pharma companies are embracing this and investing heavily, while others cut back. 

Solution from HLTH Europe: We connect you with seasoned experts to help you navigate the ever-evolving digital health landscape. Through startup pitches, interactive workshops, and compelling case studies, we showcase the proven ROI of digital health tools, equipping you with the insights and strategies needed to convince stakeholders of their strategic value.

Erosion of government and policy influence and challenges in price negotiation

Pain point: Pharma and life sciences companies face reduced access to key decision-makers in government and policymaking, limiting their ability to advocate for favourable regulations and pricing policies. Simultaneously, they are under pressure to secure the highest possible revenue during price negotiations with payers, while managing complex global market dynamics and regulatory expectations.

Solution from HLTH Europe: Our Health Transformation Summit, held in partnership with the World Economic Forum, unites ministers, senior policymakers, and regulators from around the world. HLTH Europe fosters meaningful connections with policy leaders, government representatives, and payers through exclusive networking dinners, workshops, roundtables, and tailored meetups. These high-impact engagements empower companies to rebuild influence, anticipate regulatory trends, and enhance their negotiating power - driving better pricing strategies and favorable policy outcomes.

2024 speaker highlights

David Evendon-Challis

Head of R&D and Chief Scientific Officer

Bayer Consumer Health

Switzerland

John Halamka

President, Mayo Clinic Platform

Mayo Clinic

USA

Karen DeSalvo

Chief Health Officer

Google

USA

Karen Madden

Chief Technology Officer

Merck Life Science

USA

Simon Turner

Partner

Sofinnova Partners

France

Stephen Ranjan

Global Head, Digital Health Pharma Personalized Healthcare

Roche

Switzerland

About HLTH Europe


hlth.

HLTH Europe is the continent’s #1 healthcare innovation event. Following an enormously successful first event in 2024 and the exponential growth of HLTH in the US, this landmark event is where global expertise meets local insight to address Europe's unique healthcare challenges and opportunities.

EUROPE


2025 | HLTH Europe: 16-19 June
2026 | HLTH Europe: 15-18 June
2027 | HLTH Europe: 21-24 June
2028 | HLTH Europe: 19-22 June

USA


2025 | ViVE: Feb 16-19

2025 | HLTH USA: Oct 19-22

2026 | ViVE: Feb 22-27

2026 | HLTH USA: Nov 15-18

2027 | HLTH USA: Oct 17-20


© 2025 HLTH, INC. All Rights Reserved

Join the HLTH Europe mailing list